NWPF

News ArchivesRead News

EMEA Adopts Positive Opinion On Neupro (Parkinson’s Disease) And Rotarix (Infant Gastro-Entiritis Prevention) And Others, E

Thursday December 22, 2005

17 Dec 2005(Medical News Today) - The Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions on initial marketing authorisation applications for:

-- Neupro (rotigotine), Schwarz Pharma Ltd. Neupro is indicated for the treatment of idiopathic Parkinson’s disease. EMEA review began on 18 October 2004 with an active review time of 202 days.

-- Rotarix (human rotavirus, live attenuated), GlaxoSmithKline Biologicals S.A. Rotarix is indicated for active immunisation of infants from the age of 6 weeks for prevention of gastro-enteritis due to rotavirus infection. EMEA review began on 20 December 2004 with an active review time of 175 days.

The CHMP adopted a negative opinion for Zelnorm, Novartis Europharm Limited. The indication proposed was: the repeated symptomatic short-term treatment of Irritable Bowel Syndrome in women whose predominant bowel habit is constipation. EMEA review began on 18 October 2004 with an active review time of 204 days. A question and answer document has been published and can be found on EMEA website http://www.emea.eu.int

Extensions of indications and other recommendations

The Committee adopted positive opinions on the extension of indication of medicinal products that are already authorised in the European Union.

-- Invanz (ertapenem), Merck Sharp & Dohme, to extend its indication to add diabetic foot infections of the skin and soft tissue. Invanz was first authorised in the European Union on 18 April 2002 and is currently indicated for the treatment of bacterial infections.

-- Tamiflu (oseltamivir), Roche Registration Ltd, to include children between 1 and 12 years of age in the indication prevention of influenza. Tamiflu was first authorised in the European Union on 20 June 2002 and is currently indicated for the treatment of influenza in adults and children from one year of age and for prevention of influenza in adults and adolescents of 13 years and older.

Summaries of opinions for all these products are available and can be found on EMEA website http://www.emea.eu.int

Safety updates

A review by the European Medicines Agency (EMEA) of new safety data for Tamiflu has concluded that there is no new safety signal relating to psychiatric disorders while taking Tamiflu and therefore no change to the product safety information of Tamiflu is needed.

A separate press release has been issued and can be found here. Rare cases of macular oedema (swelling of the back of the eye) have been reported with rosiglitazone- (Avandia/ Avandamet, from SmithKline Beecham) and pioglitazone- (Actos/Glustin, from Takeda Europe) containing medicinal products.

Following discussions of these post-marketing findings, the CHMP concluded that a further review should be performed to establish whether there is a possible association between macular oedema and the use of rosiglitazone and pioglitazone.

Referral procedures started

The Committee started a referral procedure for atorvastatin-containing medicinal products (Sortis and other associated names) in relation to an application submitted by Parke-Davis GmbH to extend the indication to the prevention of cardiovascular events in patients with multiple risk factors.

The procedure was initiated by Spain under Article 6(12) of Commission Regulation EC No 1084/2003 because of differences between Member States with regard to the extent of the patient population likely to benefit from atorvastatin therapy in this clinical setting.

The Committee started a referral procedure for mifepristone-containing medicinal products (Mifegyne). France triggered this referral following safety and efficacy concerns with regards to the use of the approved dose of 600 mg mifepristone in the indication of "medical termination of developing intra-uterine pregnancy in sequential use with prostaglandin analogue" as compared to the use of a 200 mg mifepristone dose. The procedure was initiated under Article 31 of Directive 2001/83/EC as amended.

Recent News

May 20 - Book Review: Aging in the Key of Humor
May 19 - Press Release: The Michael J. Fox Foundation for Parkinson's Research Joins Multinational Critical Path for Parkinson's Consortium
May 19 - Congress reaches deal to overhaul chemical regulation
May 16 - Lifestyle: Why Parkinson's disease won't stop me rowing across the Pacific
May 16 - Many biomarkers for PD fail to inform on progression
May 10 - Parkinson's Cell Transplant Shows Good Reinnervation at 24 Years
May 7 - Growing art installation gathers stories of living with Parkinson's
May 5 - New technique can provide better cell transplants against Parkinson's disease
May 2 - What's Good For The Heart Is Good For The Brain
Apr 29 - Press Release: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease
Apr 28 - Dopamine-making neurons can be chemically controlled in animal model of Parkinson's
Apr 25 - Lifestyle: Dating with Disease
Apr 25 - Scientific breakthrough in fight against Parkinson's and Alzheimer's
Apr 20 - Breakthrough Parkinson's disease blood test
Apr 15 - Living with Parkinson's
Apr 12 - Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease
Apr 11 - Yoga for Every Body: Experts say yoga can ease pain and improve mobility for people with neurologic conditions
Apr 9 - Commonly prescribed Parkinson's drugs up risk of compulsive gambling, shopping, binge eating, hypersexuality
Apr 7 - Pfizer and IBM Launch Innovative Research Project to Transform Parkinson's Disease Care
Apr 7 - Parkinson's Drug Highly Effective for Resistant Depression